1 Patients were given 1,500,000 international units (IU) of IFN
2 Patients were given 1.8 mg/m(2) inotuzumab ozogamicin intrave
3 Patients were given 10 mg/kg intravenous pembrolizumab every
4 Patients were given 10 mg/kg pembrolizumab every 2 weeks unti
5 Patients were given 1200 mg intravenous atezolizumab every 21
6 Patients were given 250 mg of ciprofloxacin orally twice dail
7 Patients were given 3 mg/kg nivolumab every 2 weeks until dis
8 After a 2-week run-in period, all
patients were given 50 mg/d of sertraline and randomized in d
9 Patients were given 60 mg of cabozantinib orally per day.
10 sted of initial conservative measures, following which, the
patients were given a choice of continuing conservative thera
11 uring a median follow-up of 7.7 years (maximum, 19.0), 1273
patients were given a diagnosis of colorectal cancer.
12 Patients were given a fixed-dose combination tablet of 90 mg
13 When
patients were given a low-dose insulin infusion, insulin sens
14 reliably improved memory compared with control images when
patients were given a recognition-memory test the next day.
15 On discharge from hospital
patients were given a salmeterol/fluticasone inhaler with an
16 These
patients were given a single daily dose of the extended-relea
17 Patients were given a structured clinical examination and com
18 Immediately after endoscopy,
patients were given a suppository containing either 100 mg di
19 All
patients were given a tarsoaponeurectomy as the basic surgica
20 Computer-simulated "
patients" were given a rapid VF (mean deviation [MD]) loss of
21 At diagnosis, 139 untreated juvenile DM
patients were given aggressive therapy (intravenous methylpre
22 Patients were given an oral, once-daily, fixed-dose combinati
23 All
patients were given appropriate supportive intensive care for
24 All
patients were given aspirin.
25 Patients were given ch14.18 for 4 days at 28-day intervals.
26 Patients were given clopidogrel (300-mg load followed by 75 m
27 Seventy-two
patients were given dexamethasone 40 mg weekly, clarithromyci
28 2135
patients were given disease-specific information about standa
29 Patients were given first-line cisplatin and gemcitabine chem
30 Three
patients were given furosemide at 30 min after the radiopharm
31 ious HIT reexposed to heparin 4.4 years (mean) post-HIT; 17
patients were given heparin intraoperatively (without postope
32 Patients were given intravenous rituximab 1 g on days 1 and 1
33 Patients were given isavuconazole 200 mg (as its intravenous
34 Prior to treatment,
patients were given medical history and dental evaluations.
35 Patients were given medical therapy (topical and/or systemic)
36 Patients were given nivolumab intravenously over 60 min at 3
37 Twenty
patients were given ombitasvir co-formulated with paritaprevi
38 Patients were given oral cannabidiol at 2-5 mg/kg per day, up
39 All
patients were given oral lenalidomide 25 mg per day for 21 of
40 In the phase 1 part of the trial,
patients were given oral ODM-201 at a starting daily dose of
41 Patients were given prednisone (10 to 40 mg/d) when the study
42 Most
patients were given radiotherapy with 3-6 months of neoadjuva
43 Patients were given simultaneous injections of buffered and u
44 All AHR
patients were given steroid pulses, but only four received an
45 Patients were given subcutaneous placebo at weeks 0-3, then u
46 asurements were made with echocardiography (every 2 years);
patients were given systematic beta-blockade and advice about
47 A total of 133
patients were given the CLUSE tool; 16 participants were excl
48 Patients were given TPCS2a on day 0 by slow intravenous injec
49 Patients were given unfractionated heparin for anticoagulatio
50 Patients were given up to a maximum of 17 cycles of treatment